Human papillomavirus type 16 E5 protein (HPV16 E5)

Human papillomavirus type 16 E5 protein (HPV16 E5) is a small, 83-amino acid hydrophobic transmembrane oncoprotein primarily expressed during the early stages of HPV16 infection [1, 5, 8]. It localizes to the endoplasmic reticulum, Golgi apparatus, and plasma membrane, where it functions as a viroporin and modulates several host cell signaling pathways [7, 15]. A primary mechanism of E5-mediated transformation is the enhancement of Epidermal Growth Factor Receptor (EGFR) signaling, achieved by binding to the 16-kDa subunit of the vacuolar H+-ATPase and inhibiting the acidification of endosomes, which prevents EGFR degradation [2, 5, 9]. E5 also plays a critical role in immune evasion by sequestering MHC class I and II molecules in the Golgi apparatus and suppressing the expression of interferon-kappa [8, 10, 13]. In the context of disease, HPV16 E5 contributes to the development of premalignant lesions and early-stage cervical and oropharyngeal cancers [1, 4, 14]. Because the E5 gene is frequently lost or downregulated when the viral genome integrates into the host DNA during progression to invasive cancer, it is considered a particularly valuable target for therapeutic intervention in early-stage disease [2, 3, 11]. Current therapeutic strategies include the development of E5-specific therapeutic vaccines and small-molecule inhibitors designed to block its ion channel activity or its interaction with host signaling proteins [14, 15].

Other names

E5Protein E5HPV-16 E5Probable protein E5Oncogene protein E5

Therapeutic vaccination to induce E5-specific T-cell responses, inhibition of viroporin ion channel activity, and modulation of E5-mediated EGFR signaling pathways.